Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New mechanisms in airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Aoki, T. Hisada, H. Tsurumaki, R. Yoshino, H. Kuwabara, T. Ishizuka, K. Dobashi, M. Mori (Maebashi, Japan). Late-breaking abstract: Relationship with hemoglobin A1c and exacerbations of COPD. A preliminary study. Eur Respir J 2011; 38: Suppl. 55, 3413

Member's Comments

No comment yet.

Related content which might interest you: Positive airway pressure treatment reduces glycated hemoglobin (HbA1c) levels in obstructive sleep apnea patients: Longitudinal data from the ESADA Source: International Congress 2019 – Current perspectives in sleep-disordered breathing Year: 2019 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014 Late-breaking abstract: Factors associated with medication adherence in patients with COPD Source: Annual Congress 2011 - Diagnosis and predictors of COPD exacerbation Year: 2011 Diagnosis of COPD exacerbations on hospital admission: Results from the European COPD audit Source: Annual Congress 2011 - Diagnosis and predictors of COPD exacerbation Year: 2011 Glycated hemoglobin (HbA1c) and acute exacerbation in chronic obstructive pulmonary disease: a potent biomarker of severity and prognosis. Preliminary data. Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Phenotypical heterogeneity of severe COPD subjects: Baseline results from the Czech multicentre research database of COPD Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Agreement between patient-reported and chart documented outcomes: Case study in COPD Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013 Preliminary results of relationship between appetite and clinical presentation of COPD patients in AERIS study Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Late-breaking abstract: Nasal symptoms are common in subjects with COPD and concomitant heart disease Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011 Stable state MR-proadrenomedullin level in COPD patients; a validation study Source: International Congress 2014 – Comorbidities Year: 2014 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Increased plasma haemoglobin A1c (HbA1c) concentration and cardiovascular complications in obstructive sleep apnoea (OSA) patients with and without diabetes Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009 Observational study to characterise 24-hour COPD symptoms: Interim analysis of ASSESS Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 Haemoglobin level and its clinical impact in a cohort of patients with COPD Source: Eur Respir J 2007; 29: 923-929 Year: 2007 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016